Case details

Merger control

Case reference

CCENT/2008/64 - MAGNUM/PPS/FARMA APS

Acquired

APS

Description

a Portuguese-registered company that operates in Portugal and Spain in the development, manufacture and marketing of pharmaceutical products, including generic medicines, directly and through the following companies: Generis - Farmacêutica SA and Biogeneris - Farmacêutica SA.

Acquiring

Magnum

Description

a Scottish limited partnership, created under British law; it carries out investments, for the purpose of creating value, in large and medium-sized Portuguese and Spanish undertakings, potentially in all sectors, with the exception of the areas of finance and property promotion;

Acquiring

PPS

Description

the current minority shareholder in FARMA APS, who owns controlling shareholdings in other companies, namely: (i) Inventis - Farmacêutica e Biotecnologia SA, which markets medication dossiers; and (ii) Mer Medicamentos Lda, which markets medicines for human use;

Sector

Extractive and manufacturing Industries

Activity (NACE)

C21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations

Applicable legislation

Art. 9(1)(a) and (b) (Law 18)

Notification thresholds

Turnover and market share

Type of merger

Horizontal

Cooperation with sector regulators

Status

Closed

Type of Investigation

Phase 1

AdC’s decision

Case description

Notified on 3 December 2008, this merger consists of the acquisition by Magnum Capital LP (henceforth "MAGNUM") and the individual shareholder Paulo Paiva dos Santos (henceforth "PPS"), via the company Inventis - Farmacêutica e Biotecnologia SA or another company established for the purpose, of joint control of FARMA APS - Produtos Farmacêuticos SA (henceforth "FARMA APS").

Timeline

2008-12-23

COMPETITION AUTHORITY adopts a decision of non-opposition to merger operation CCENT. No. 64/2008: MAGNUM/PPS/FARMA APS

2008-12-04

Publication of the announcement

Top links

Case details